Cytosorbents (NASDAQ:CTSO) Earns Neutral Rating from HC Wainwright

Cytosorbents (NASDAQ:CTSO)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $1.00 target price on the medical research company’s stock. HC Wainwright’s target price would suggest a potential upside of 11.11% from the company’s previous close.

Other analysts have also recently issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Friday, May 2nd. StockNews.com began coverage on Cytosorbents in a research report on Tuesday. They issued a “hold” rating for the company.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO opened at $0.90 on Thursday. The business’s 50-day moving average price is $1.00 and its two-hundred day moving average price is $0.99. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a one year low of $0.70 and a one year high of $1.61. The company has a market capitalization of $56.35 million, a P/E ratio of -2.50 and a beta of 1.17.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The firm had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.01 million. Analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

A number of institutional investors and hedge funds have recently made changes to their positions in CTSO. Skylands Capital LLC lifted its position in shares of Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Cytosorbents during the 4th quarter worth about $99,000. Renaissance Technologies LLC lifted its position in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Avenir Corp lifted its position in shares of Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after purchasing an additional 118,387 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.